2. Search Result
Search Result
Results for "

159351-69-6

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-10218
    Everolimus
    110+ Cited Publications

    RAD001; SDZ-RAD

    		 mTOR FKBP Autophagy Apoptosis Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus
  • HY-10218R
    Everolimus (Standard)

    RAD001 (Standard); SDZ-RAD (Standard)

    		 Reference Standards mTOR FKBP Autophagy Apoptosis Bacterial Cancer
    Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus (Standard)
  • HY-10218S
    Everolimus-d4

    RAD001-d4; SDZ-RAD-d4

    		 mTOR FKBP Autophagy Apoptosis Cancer
    Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-d4
  • HY-10218S1
    Everolimus-13C2,d4

    RAD001-13C2,d4; SDZ-RAD-13C2,d4

    		 Isotope-Labeled Compounds Bacterial Autophagy FKBP mTOR Apoptosis Cancer
    Everolimus- 13C2,d4 (RAD001- 13C2,d4) is 13C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-13C2,d4

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: